A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

PURPOSE: The standard of care in the neoadjuvant setting for human epidermal growth factor receptor 2 (HER2)-positive breast cancer is dual HER2-targeted therapy. However, a need to minimize treatment-related toxicity and improve pathological complete response (pCR) rates, particularly in luminal HE...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Norikazu, Ohtani, Shoichiro, Takano, Toshimi, Inoue, Kenichi, Suzuki, Eiji, Nakamura, Rikiya, Bando, Hiroko, Ito, Yoshinori, Ishida, Kazushige, Yamanaka, Takashi, Kuroi, Katsumasa, Yasojima, Hiroyuki, Kasai, Hiroi, Takasuka, Tsuyoshi, Sakurai, Takaki, Kataoka, Tatsuki R., Morita, Satoshi, Ohno, Shinji, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031180/
https://www.ncbi.nlm.nih.gov/pubmed/31953696
http://dx.doi.org/10.1007/s10549-020-05524-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031180/
https://www.ncbi.nlm.nih.gov/pubmed/31953696
http://dx.doi.org/10.1007/s10549-020-05524-6

Ejemplares similares